AbbVie and Genmab touted results from a Phase 3 combination study for Epkinly (epcoritamab) after a prior monotherapy setback in diffuse large B-cell lymphoma. In the Epcore DLBCL-4 trial, Epkinly plus lenalidomide cut the risk of progression or death by 60% versus R-GemOx, meeting the trial’s primary endpoint. The companies also highlighted the safety profile as consistent with prior experience and noted a progression-free survival improvement of 56% for non-U.S. regulators using a comparable analysis approach. No overall survival results were disclosed in the initial release. With another high-stakes readout expected in Epcore DLBCL-2 for first-line disease, this update reframes the Epkinly outlook toward combination strategy and intensifies competitive pressure in second-line lymphoma after prior FDA refusals for competing bispecific regimens.